Key result
Following everolimus-eluting stent implantation, the cumulative rate of major bleeding was 10.8% at 8 years, while definite stent thrombosis occurred in only 0.4% of patients.
Why the study?
The long-term incidence and details of major bleeding and coronary thrombotic events in patients receiving everolimus-eluting stents have not been clear.
Cohort (n=1,193)
No
Major bleeding is a persistent long-term hazard up to 8 years after everolimus-eluting stent implantation, whereas stent thrombosis remains very rare.
Answers are grounded in this paper and cite their sources.
Persistent bleeding risk up to 8 years post-stent warrants caution; extends observational data but leaves optimal DAPT duration open.
BACKGROUND: To date, the long-term incidence and details of major bleeding (MB) and coronary thrombotic events (CTE) in patients with everolimus-eluting stent (EES) implantation have not been made clear. METHODS AND RESULTS: The study population comprised 1,193 patients treated with EES without in-hospital events between 2010 and 2011. MB was defined as the occurrence of a Bleeding Academic Research Consortium type 3 or 5 bleeding event. The mean follow-up period was 2,996±433 days. Cumulative rate of MB was 7.4% and 10.8% at 5 and 8 years, respectively. Of 46 patients with intracranial bleeding, 20 had trauma-related intracranial bleeding. Cumulative rates of definite stent thrombosis and CTE at 8 years were 0.4% and 5.9%, respectively. Multivariate analysis revealed low body mass index (<23) (hazard ratio (HR), 1.57; 95% confidence interval (CI), 1.03-2.36; P=0.03) and concomitant use of oral anticoagulants (HR, 2.17; 95% CI, 1.30-3.50; P=0.004) as independent risk factors of MB and previous PCI (HR, 2.47; 95% CI, 1.29-1.00; P=0.006) as the factor for CTE. CONCLUSIONS: MB is not uncommon and is a long-term hazard, but the occurrence of stent thrombosis is very low after EES implantation. Approximately half of the cases involving intracranial bleeding were associated with trauma.
No takes yet. Share an insight, caveat, or question.
Miura et al. (2019) conducted a cohort in Coronary artery disease requiring percutaneous coronary intervention (n=1,193). Everolimus-eluting stent implantation was evaluated on Cumulative rate of major bleeding (BARC type 3 or 5) at 8 years. Following everolimus-eluting stent implantation, the cumulative rate of major bleeding was 10.8% at 8 years, while definite stent thrombosis occurred in only 0.4% of patients.
Synapse has enriched 10 related papers. Consider them for comparative context: